The 23rd China International In Vitro Diagnostics by CACLP was successfully held from 21-23 March 2026 in Xiamen, marking another milestone in the event’s continued expansion across China, Southeast Asia and the global market.

In order to promote innovative exchanges and cross-regional cooperation in the global in vitro diagnostics field, the 1st Global IVD Innovation Summit is scheduled to be held in Xiamen on March 22, 2026, during CACLP 2026. Hereby notify the relevant matters as follows:

As artificial intelligence and digital twin technologies rapidly reshape the global healthcare landscape, their integration into clinical practice, laboratory medicine, and biomedical research is opening new frontiers for precision, efficiency, and system-level optimization.

As the global in vitro diagnostics (IVD) industry undergoes rapid technological evolution and market restructuring, overseas expansion has become a key growth pathway for Chinese IVD companies.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

China leads the world in AI research publications related to the global medical device field over the past five years, according to a latest industrial white paper.

Livzon Pharmaceutical Group said it will take a controlling stake in Vietnam’s Imexpharm for VND5.73 trillion (USD220.7 million) so as to further expand the Chinese drugmaker’s business overseas.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The global IVD market is expected to realize +3% CAGR, (+5% CAGR excluding COVID-19), notably stemming from emerging region from 2023-2028.

As China’s in vitro diagnostic (IVD) industry continues its rapid development, numerous outstanding enterprises have made remarkable achievements in research and development, production, and market expansion.